Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer

Open access

Abstract

BACKGROUND: Programmed death ligand-1 (PD-L1) has been identified as a factor associated with poor prognosis in a range of cancers, and was reported to be mainly induced by PTEN loss in gliomas. However, the clinical effect of PD-L1 and its regulation by PTEN has not yet been determined in colorectal cancer (CRC). In the present study, we verified the regulation of PTEN on PD-L1 and further determined the effect of PTEN on the correlation between PD-L1 expression and clinical parameters in CRC. METHODS/RESULTS: RNA interference approach was used to down-regulate PTEN expression in SW480, SW620 and HCT116 cells. It was showed that PD-L1 protein, but not mRNA, was significantly increased in cells transfected with siRNA PTEN compared with the negative control. Moreover, the capacity of PTEN to regulate PD-L1 expression was not obviously affected by IFN-γ, the main inducer of PD-L1. Tissue microarray immunohistochemistry was used to detect PD-L1 and PTEN in 404 CRC patient samples. Overexpression of PD-L1 was significantly correlated with distant metastasis (P<0.001), TNM stage (P<0.01), metastatic progression (P<0.01) and PTEN expression (P<0.001). Univariate analysis revealed that patients with high PD-L1 expression had a poor overall survival (P<0.001). However, multivariate analysis did not support PD-L1 as an independent prognostic factor (P = 0.548). Univariate (P<0.001) and multivariate survival (P<0.001) analysis of 310 located CRC patients revealed that high level of PD-L1 expression was associated with increased risks of metastatic progression. Furthermore, the clinical effect of PD-L1 on CRC was not statistically significant in a subset of 39 patients with no PTEN expression (distant metastasis: P = 0.102; TNM stage: P = 0.634, overall survival: P = 0.482). CONCLUSIONS: PD-L1 can be used to identify CRC patients with high risk of metastasis and poor prognosis. This clinical manifestation may be partly associated with PTEN expression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0065821

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Not PTEN loss but IFN-γ induced PD-L1 mRNA expression in CRC cell lines. (A) The relative expression level of PTEN mRNA (detected by qRT-PCR, calculated by 2−ΔΔCT method) in four groups: cells transfected with siRNA PTEN or non-specific sequences in the presence or absence of IFN-γ. (B) The relative expression level of PD-L1 mRNA in four groups of cells. Data were collected from three independent experiments. Error bars represent SD.
Figure 1 Not PTEN loss but IFN-γ induced PD-L1 mRNA expression in CRC cell lines. (A) The relative expression level of PTEN mRNA (detected by qRT-PCR, calculated by 2−ΔΔCT method) in four groups: cells transfected with siRNA PTEN or non-specific sequences in the presence or absence of IFN-γ. (B) The relative expression level of PD-L1 mRNA in four groups of cells. Data were collected from three independent experiments. Error bars represent SD.CC BY · PubMed Central
Figure 2 PTEN knockdown increased Akt activation both in the presence and absence of IFN-γ. The protein expression level of PTEN, Akt and phospho-AktSer473 were determined by Western blotting. β-actin was used to verify equal loading. Representative images are selected from performed experiments repeated in triplicates.
Figure 2 PTEN knockdown increased Akt activation both in the presence and absence of IFN-γ. The protein expression level of PTEN, Akt and phospho-AktSer473 were determined by Western blotting. β-actin was used to verify equal loading. Representative images are selected from performed experiments repeated in triplicates.CC BY · PubMed Central
Figure 3 Effect of IFN-γ and PTEN loss on the expression of PD-L1 protein. PD-L1 protein expression level on the surface of SW480, SW620 and HCT116 was determined by flow cytometer: cells transfected with siRNA PTEN (red lines) and cells transfected with non-specific sequences (blue lines) in the absence of IFN-γ; cells transfected with siRNA PTEN (black lines) and cells transfected with non-specific sequences (orange lines) in the presence of IFN-γ; cells stained with isotype-matched control antibody (shaded area). Standard fluorescence intensity of PD-L1 protein was described by histogram in right panel: cells treated (white column) or untreated (gray column) with IFN-γ. Data were collected from three independent experiments. Error bars represent SD. (*P<0.05 by paired-samples t test).
Figure 3 Effect of IFN-γ and PTEN loss on the expression of PD-L1 protein. PD-L1 protein expression level on the surface of SW480, SW620 and HCT116 was determined by flow cytometer: cells transfected with siRNA PTEN (red lines) and cells transfected with non-specific sequences (blue lines) in the absence of IFN-γ; cells transfected with siRNA PTEN (black lines) and cells transfected with non-specific sequences (orange lines) in the presence of IFN-γ; cells stained with isotype-matched control antibody (shaded area). Standard fluorescence intensity of PD-L1 protein was described by histogram in right panel: cells treated (white column) or untreated (gray column) with IFN-γ. Data were collected from three independent experiments. Error bars represent SD. (*P<0.05 by paired-samples t test).CC BY · PubMed Central
Figure 4 Dosage-course and time-course effect of IFN-γ on PD-L1 in SW480. (A) SW480 treated with IFN-γ at indicated concentration (0 IU/ml, 50 IU/ml, 100 IU/ml, 500 IU/ml, 1000 IU/ml). (B) SW480 treated with 500 IU/ml IFN-γ for indicted times (0 h, 24 h, 48 h, and 72 h). Shaded area represents SW480 without treatment of IFN-γ, and numbers next to peaks represent standard fluorescence intensity of PD-L1. Representative images are selected from performed experiments repeated in triplicates.
Figure 4 Dosage-course and time-course effect of IFN-γ on PD-L1 in SW480. (A) SW480 treated with IFN-γ at indicated concentration (0 IU/ml, 50 IU/ml, 100 IU/ml, 500 IU/ml, 1000 IU/ml). (B) SW480 treated with 500 IU/ml IFN-γ for indicted times (0 h, 24 h, 48 h, and 72 h). Shaded area represents SW480 without treatment of IFN-γ, and numbers next to peaks represent standard fluorescence intensity of PD-L1. Representative images are selected from performed experiments repeated in triplicates.CC BY · PubMed Central
Figure 5 Representative Immunohistochemical results of PD-L1/PTEN for patients with and without metastatic progression. (A1, A2, E1, E2) Negative control; (B1, B2, F1, F2) Specimens from the same patient with metastatic progression; (C1, C2, G1, G2) Specimens from another patient without metastatic progression; (D1, D2) A typical representative which showed that PD-L1 expression is elevated in the tumor area (T) compared with those of adjacent normal mucosa (N); (H1, H2) Specimens from patient without any PTEN expression; (J, K) Statistical analysis demonstrated that PD-L1 expression is increased in the patients with metastatic progression compared with those without metastatic progression, while such statistical analysis of PTEN wasn’t significant. (Two up panels, stained with PD-L1 antibody; two down panels, stained with PTEN antibody), (A1–H1, ×100; A2–H2, ×400).
Figure 5 Representative Immunohistochemical results of PD-L1/PTEN for patients with and without metastatic progression. (A1, A2, E1, E2) Negative control; (B1, B2, F1, F2) Specimens from the same patient with metastatic progression; (C1, C2, G1, G2) Specimens from another patient without metastatic progression; (D1, D2) A typical representative which showed that PD-L1 expression is elevated in the tumor area (T) compared with those of adjacent normal mucosa (N); (H1, H2) Specimens from patient without any PTEN expression; (J, K) Statistical analysis demonstrated that PD-L1 expression is increased in the patients with metastatic progression compared with those without metastatic progression, while such statistical analysis of PTEN wasn’t significant. (Two up panels, stained with PD-L1 antibody; two down panels, stained with PTEN antibody), (A1–H1, ×100; A2–H2, ×400).CC BY · PubMed Central
Figure 6 Association of PD-L1/PTEN expression with overall survival (OS) and metastasis-free survival (MFS) in 347 CRC patients. (A, B) The OS and MFS were significantly lower in PD-L1-higher-expression patients compared with PD-L1-lower-expression patients (both P<0.001). (C, D) The OS and MFS were not significantly different between the PTEN-higher-expression patients and the PTEN-lower-expression patients (OS, P = 0.366; MFS, P = 0.141). (E) In the subset of 39 patients with complete PTEN loss, PD-L1 expression was no longer associated with the OS (P = 0.482).
Figure 6 Association of PD-L1/PTEN expression with overall survival (OS) and metastasis-free survival (MFS) in 347 CRC patients. (A, B) The OS and MFS were significantly lower in PD-L1-higher-expression patients compared with PD-L1-lower-expression patients (both P<0.001). (C, D) The OS and MFS were not significantly different between the PTEN-higher-expression patients and the PTEN-lower-expression patients (OS, P = 0.366; MFS, P = 0.141). (E) In the subset of 39 patients with complete PTEN loss, PD-L1 expression was no longer associated with the OS (P = 0.482).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Research works printed but not linked: 1

  1. CE Gillett, 2000, Multiple tissue core arrays in histopathology research: a validation study, J Pathol, 192, 549, 10.1002/1096-9896(2000)9999:9999<::AID-PATH721>3.0.CO;2-0 · doi:10.1002/1096-9896(2000)9999:9999<::aid-path721>3.0.co;2-0

Cited by

See all 266

Metadata

Authors
Song, M., Chen, D., Lu, B., Wang, C., Zhang, J., Huang, L., Wang, X., Timmons, C. L., Hu, J., Liu, B., Wu, X., Wang, L., Wang, J., & Liu, H.
Affiliations
  • Sun Yat-sen University (CN)
  • Meharry Medical College (US)
Corresponding author
  • Wang, Jianping
  • Liu, Huanliang
Venue
PLoS ONE
Published
2013-06-13
Volume
8
Issue
6
Pages
e65821
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2082431132
Cited by
266
References
37
Citations by year
2026: 2 · 2025: 10 · 2024: 17 · 2023: 22 · 2022: 22 · 2021: 24 · 2020: 29 · 2019: 29 · 2018: 31 · 2017: 31 · 2016: 18 · 2015: 21 · 2014: 7 · 2013: 3
FWCI
8.74
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Sun Yat-sen University (985 Project)
  • Guangdong Province Introduction of Innovative R&D Team (2009010058)
  • National Center for Research Resources (U54RR026140)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
PTEN loss, PD-L1 expression, colorectal cancer, tumor suppressor regulation, distant metastasis, TNM stage, prognostic factors, overall survival, interferon-gamma, metastatic progression
MeSH terms
Aged, Aged, 80 and over, Enzyme Activation, Female, Follow-Up Studies, Humans, Interferon-gamma, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Colorectal Neoplasms, Gene Expression Regulation, Neoplastic, Cell Line, Tumor, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase, Gene Knockdown Techniques, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer. https://app.cochat.ai/papers/10.1371/journal.pone.0065821
The paper
Song, M., Chen, D., Lu, B., Wang, C., Zhang, J., Huang, L., Wang, X., Timmons, C. L., Hu, J., Liu, B., Wu, X., Wang, L., Wang, J., & Liu, H. (2013). PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer. PLoS ONE. https://doi.org/10.1371/journal.pone.0065821

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.